US 11,872,222 B2
Uses
Mike Trower, Stevenage (GB); Stephen Pawsey, Stevenage (GB); and Mary Kerr, Stevenage (GB)
Assigned to NeRRe Therapeutics Limited, Stevenage (GB)
Filed by NeRRe Therapeutics Limited, Stevenage (GB)
Filed on May 28, 2021, as Appl. No. 17/333,415.
Claims priority of provisional application 63/033,279, filed on Jun. 2, 2020.
Prior Publication US 2021/0369707 A1, Dec. 2, 2021
Int. Cl. A61K 31/4985 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/4985 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2054 (2013.01)] 11 Claims
 
1. A method of treating pulmonary fibrosis promoted by mechanical injury to the lungs of a patient with idiopathic pulmonary fibrosis (IPF), said method comprising administering to said patient a therapeutically effective amount of orvepitant or a pharmaceutically acceptable salt thereof.